Arrowhead Pharmaceuticals Stock Investor Sentiment
| ARWR Stock | USD 19.56 0.54 2.84% |
Slightly above 52% of Arrowhead Pharmaceuticals' retail investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Arrowhead Pharmaceuticals suggests that some traders are interested. Arrowhead Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Arrowhead Pharmaceuticals. Many technical investors use Arrowhead Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Panic Vs Confidence
52
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Arrowhead Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Arrowhead Pharmaceuticals.
News SentimentBullish | Hype SentimentBullish | Insider SentimentDisposing |
Arrowhead Historical Sentiment
Although Arrowhead Pharmaceuticals' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Arrowhead, such as negative comments on social media and news outlets, may cause fear in the market and push Arrowhead Pharmaceuticals' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Arrowhead.
Arrowhead |
Arrowhead Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Arrowhead Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Arrowhead Pharmaceuticals Historical Investor Sentiment
Investor biases related to Arrowhead Pharmaceuticals' public news can be used to forecast risks associated with an investment in Arrowhead. The trend in average sentiment can be used to explain how an investor holding Arrowhead can time the market purely based on public headlines and social activities around Arrowhead Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Arrowhead Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Arrowhead Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Arrowhead Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Arrowhead Pharmaceuticals.
Far too much social signal, news, headlines, and media speculation about Arrowhead Pharmaceuticals that are available to investors today. That information is available publicly through Arrowhead media outlets and privately through word of mouth or via Arrowhead internal channels. However, regardless of the origin, that massive amount of Arrowhead data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Arrowhead Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Arrowhead Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Arrowhead Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Arrowhead Pharmaceuticals alpha.
Arrowhead Pharmaceuticals Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | In the wake of Arrowhead Pharmaceuticals, Inc.s latest US108m market cap drop, institutional owners may be forced to take severe actions | 11/01/2024 |
2 | Chardan sustains buy rating on Arrowhead shares post-Sarepta deal | 11/27/2024 |
3 | Arrowhead Pharmaceuticals, Inc. Short Interest Up 6.6 percent in November | 12/16/2024 |
4 | Disposition of 547 shares by Given Douglas B of Arrowhead Pharmaceuticals at 22.04 subject to Rule 16b-3 | 12/17/2024 |
5 | Disposition of 5799 shares by Christopher Anzalone of Arrowhead Pharmaceuticals at 22.12 subject to Rule 16b-3 | 12/18/2024 |
6 | Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635 | 12/19/2024 |
7 | Arrowhead Pharmaceuticals Initiates Phase 12a Study of ARO-INHBE for the Treatment of Obesity | 12/23/2024 |
8 | Disposition of 2850 shares by Olukotun Adeoye Y of Arrowhead Pharmaceuticals at 20.0 subject to Rule 16b-3 | 12/27/2024 |
9 | Disposition of 11520 shares by Christopher Anzalone of Arrowhead Pharmaceuticals at 19.05 subject to Rule 16b-3 | 01/02/2025 |
10 | Acquisition by Obrien Patrick of 100000 shares of Arrowhead Pharmaceuticals subject to Rule 16b-3 | 01/03/2025 |
11 | Disposition of 10000 shares by Kenneth Myszkowski of Arrowhead Pharmaceuticals at 19.69 subject to Rule 16b-3 | 01/07/2025 |
12 | What is B. Rileys Forecast for ARWR FY2025 Earnings | 01/08/2025 |
13 | Arrowhead Pharmaceuticals Plozasiran NDA Accepted by FDA for Familial Chylomicronemia Syndrome | 01/17/2025 |
Additional Tools for Arrowhead Stock Analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.